Published in AIDS Weekly, August 6th, 2001
"Small compounds capable of blocking the [SDF-1] receptor CXCR4 may be potentially useful as anti-inflammatory, antiallergic, immunomodulatory, and antihuman immunodeficiency virus (HIV) agents," explained Stefano Marullo and colleagues at Cochin Hospital in Paris and other institutions.
Substituted SDF-1-based compounds can be developed that have an improved ability to compete with HIV for the CXCR4...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of AIDS Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.